Evidence map›Paper›PMID 31823734›Full record

ArticleBMC infectious diseases2019

Multicenter evaluation of TB-SPRINT 59-Plex Beamedex®: accuracy and cost analysis.

Regina Bones Barcellos, Isabela Neves de Almeida, Elisangela Costa da Silva, Harrison Magdinier Gomes, Lida Jouca de Assis Figueredo, Maria Laura Halon, Elis Regina Dalla Costa, Ícaro Rodrigues Dos Santos, Maria Cláudia Vater, Suely Alves and 6 more

Open access · goldAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Regina Bones BarcellosCentro de Desenvolvimento Científico e Tecnológico (CDCT), Secretaria Estadual da Saúde do Rio Grande do Sul (SES/RS), Porto Alegre, RS, Brazil. reginabbarcellos@gmail.com.ORCID http://orcid.org/0000-0003-0901-2422
Isabela Neves de AlmeidaLaboratório de Pesquisa em Micobactérias, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
Elisangela Costa da SilvaCentro de Pesquisa em Tuberculose, Faculdade de Medicina, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Harrison Magdinier GomesLaboratório de Biologia Molecular Aplicada a Micobactérias, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
Lida Jouca de Assis FigueredoLaboratório de Pesquisa em Micobactérias, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
Maria Laura HalonCentro de Desenvolvimento Científico e Tecnológico (CDCT), Secretaria Estadual da Saúde do Rio Grande do Sul (SES/RS), Porto Alegre, RS, Brazil.
Elis Regina Dalla CostaCentro de Desenvolvimento Científico e Tecnológico (CDCT), Secretaria Estadual da Saúde do Rio Grande do Sul (SES/RS), Porto Alegre, RS, Brazil.
Ícaro Rodrigues Dos SantosLaboratório de Biologia Molecular Aplicada a Micobactérias, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
Maria Cláudia VaterCentro de Pesquisa em Tuberculose, Faculdade de Medicina, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Suely AlvesCentro de Pesquisa em Tuberculose, Faculdade de Medicina, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Wânia da Silva CarvalhoFaculdade de Farmácia (UFMG), Belo Horizonte, MG, Brazil.
Philip SuffysLaboratório de Biologia Molecular Aplicada a Micobactérias, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
Christophe SolaInstitute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 91198, Gif-sur-Yvette cedex, France.
Silvana Spíndola de MirandaLaboratório de Pesquisa em Micobactérias, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
Maria Lucia RossettiCentro de Desenvolvimento Científico e Tecnológico (CDCT), Secretaria Estadual da Saúde do Rio Grande do Sul (SES/RS), Porto Alegre, RS, Brazil.
Afrânio KritskiCentro de Pesquisa em Tuberculose, Faculdade de Medicina, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Universidade Federal do Rio de Janeiro · BRFundação Estadual de Produção e Pesquisa em Saúde · BRFundação Oswaldo Cruz · BRUniversidade Federal de Minas Gerais · BRAstraZeneca (Brazil) · BRUniversité Paris-Sud · FR

Funding

CNPq 306759/2017-9CNPq 310174/2017-7CNPq 446796/2014CNPq 465318/2014-2PPSUS CDS - APQ-03266-13
6 · The paper itself

Abstract

backgroundMolecular tests can allow the rapid detection of tuberculosis (TB) and multidrug-resistant TB (MDR-TB). TB-SPRINT 59-Plex Beamedex® is a microbead-based assay developed for the simultaneous spoligotyping and detection of MDR-TB. The accuracy and cost evaluation of new assays and technologies are of great importance for their routine use in clinics and in research laboratories. The aim of this study was to evaluate the performance of TB-SPRINT at three laboratory research centers in Brazil and calculate its mean cost (MC) and activity-based costing (ABC).

methodsTB-SPRINT data were compared with the phenotypic and genotypic profiles obtained using Bactec™ MGIT™ 960 system and Genotype® MTBDRplus, respectively.

resultsCompared with MGIT, the accuracies of TB-SPRINT for the detection of rifampicin and isoniazid resistance ranged from 81 to 92% and 91.3 to 93.9%, respectively. Compared with MTBDRplus, the accuracies of TB-SPRINT for rifampicin and isoniazid were 99 and 94.2%, respectively. Moreover, the MC and ABC of TB-SPRINT were USD 127.78 and USD 109.94, respectively.

conclusionTB-SPRINT showed good results for isoniazid and rifampicin resistance detection, but still needs improvement to achieve In Vitro Diagnostics standards.

Indexed as

Drug Resistance, BacterialAntitubercular AgentsBacterial ProteinsCatalaseCosts and Cost AnalysisDNA-Directed RNA PolymerasesFlow CytometryGenotypeHumansIsoniazidMicrobial Sensitivity TestsMutationMycobacterium tuberculosisPromoter Regions, GeneticReagent Kits, DiagnosticRifampinAntitubercular AgentsBacterial ProteinsCatalaseDNA-Directed RNA PolymerasesIsoniazidkatG protein, Mycobacterium tuberculosisReagent Kits, DiagnosticRifampinrpoB protein, Mycobacterium tuberculosisGenotype MTBDRplusIsoniazidResistanceRifampicinTB-SPRINTTuberculosis

Identifiers

PMID31823734
PMCPMC6905027
OpenAlexW2994950050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.